Psychotic Disorder Clinical Trial
Official title:
Treating Early Stages Of seveRe Mental disOrders With an Intervention Targeting Cognitive Reserve
This study proposes continuity in the implementation of a psychological approach program to enhance cognitive reserve (CR) in children, adolescent and young adults, off-springs of patients with schizophrenia or bipolar disorder (Off-SZBP), and first affective and non-affective episodes with three main objectives: to characterize the cognitive reserve in the early stages of the disease, to validate the adaptation of the intervention to first affective and non-affective disorders to assess the effectiveness of the intervention in a longer term.
The study will include a sample of High Genetic Risk-SZBD (HR-SZBD) subjects (N = 60), First Episode Psychotic Patients (FEP) (N = 60) and CC participants (N = 60). All groups will be evaluated with CR scales as well as clinical, neuropsychological, and neuroimaging tests at baseline. The FEP and HR-SZBD groups will then be randomly allocated to a psychological intervention to enhance CR (N = 30 FEP and 30 HR-SZBD) or a support group (N = 30 FEP and 30 HR-SZBD). Once the psychological intervention (3 months) is completed, the FEP and HR-SZBD groups will be re-assessed with the same clinical, neuropsychological, and neuroimaging tests as well as CR scales that were used at baseline. Between the third and twelfth month, follow-up sessions will be conducted to remind the participants of the contents of the intervention. Finally, clinical, CR, neuropsychological and neuroimaging assessments will be completed in the FEP, HR-SZBD and CC groups at 12 months to verify whether the effects of the intervention remain stable over time. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
| Active, not recruiting |
NCT00627029 -
Evaluation of Programs of Coordinated Care and Disease Management
|
N/A | |
| Terminated |
NCT00049738 -
Screening for Childhood-Onset Psychotic Disorders
|
N/A | |
| Withdrawn |
NCT01724372 -
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
|
N/A | |
| Completed |
NCT00716755 -
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
|
N/A | |
| Completed |
NCT00498550 -
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
|
Phase 4 | |
| Terminated |
NCT04140773 -
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
|
N/A | |
| Completed |
NCT01473550 -
Mental Health Engagement Network (MHEN)
|
N/A | |
| Completed |
NCT01207219 -
Yoga and Aerobic Exercise in Psychosis
|
N/A | |
| Completed |
NCT00397033 -
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
|
Phase 3 | |
| Recruiting |
NCT04945278 -
Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability
|
N/A | |
| Completed |
NCT03955250 -
Mobile After-Care Support App: Pilot RCT
|
N/A | |
| Completed |
NCT00287352 -
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
|
Phase 1 | |
| Completed |
NCT00005658 -
Glycine to Treat Psychotic Disorders in Children
|
Phase 2 | |
| Terminated |
NCT00169026 -
Alcoholism and Schizophrenia: Effects of Clozapine
|
Phase 4 | |
| Completed |
NCT00001482 -
New Drugs in the Treatment of Mood Disorders
|
Phase 2 | |
| Terminated |
NCT03671005 -
Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders
|
N/A | |
| Completed |
NCT00156715 -
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
|
Phase 4 | |
| Completed |
NCT00095524 -
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
| Completed |
NCT03667729 -
The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia
|
N/A |